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Abstract 
Review on FGF1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: AFGF, ECGF, ECGF-beta, ECGFA, 
ECGFB, FGF-1, FGF-alpha, FGFA, GLIO703, 
HBGF-1, HBGF1 
HGNC (Hugo): FGF1 
Location: 5q31.3 
 
DNA/RNA 
Description 
The FGF1 gene is located chromosome 5 from 
141971743 to 142077617 (105893 bp) on the minus 
strand. 
Transcription 
The FGF1 gene has 12 splice variants shown in 
Ensembl database. Nine of transcripts are protein-
coding isoforms and 3 of those have no protein 
product.  
 
Figure1. FGF1 gene spans 105,89 kb on chromosome 5 in the region of q31.3 on the minus strand. It consists of 3 coding exons 
and 4 untranslated exons. The transcription is regulated by four distinct promoters. These are separated in the different 5' 
untranslated exons, designated 1A, 1B, 1C and 1D. 
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Figure 2. Schematic representation of the human FGF1 isoforms. 
 
The FGF1 gene transcript is basically composed of 
4 exons and second to fourth exons are protein-
coding. 
The transcription is regulated by at least 4 distinct 
promoters in different upstream untranslated exons, 
designated 1A, 1B, 1C, and 1D. 
These are alternatively spliced to the first protein-
coding exon (Chiu et al., 2001). The promoter 1A 
derived transcript dominantly expresses in the 
kidney (Myers et al., 1993), 1B in the brain and 
retina (Myers et al., 1993; Myers et al., 1995), and 
1C and 1D in vascular smooth muscle cells and 
fibroblasts (Chotani et al., 2000). 
Protein 
Description 
FGFs control multiple biological processes such as 
proliferation, survival, migration and differentiation 
of a variety of cell types (Lanner and Rossant, 
2010; Guillemot and Zimmer, 2011). The human 
and mouse FGF family consists of 22 members that 
are expressed in almost all tissues. Among the FGF 
family, FGF1 and FGF2 are prototypic FGF and 
have been extensively characterized. They were 
originally isolated from the brain and pituitary as 
mitogens for fibroblast cells in vitro 
(Gospodarowicz, 1975; Itoh and Ornitz, 2011). 
FGF1 contains characteristic β-trefoil structure, 
since FGF1 contains 12 antiparallel β strands which 
assemble into a pattern with threefold internal 
symmetry (Zhu et al., 1991, Brych et al., 2001). 
Key residues responsible for Interaction between 
FGF1 and heparin or its receptor are characterized  
by crystal structure (Pellegrini et al., 2000; 
Mohammadi et al., 2005a; Mohammadi et al., 
2005b). 
FGF1 is unique among FGFs because of its ability 
to bind and activate all known FGFRs, FGF1 is 
considered to be the universal FGFR ligand (Zhang 
et al., 2006).  
Comparison of the crystal structures of FGF1-
FGFR1c, FGF1-FGFR2c, and FGF1-FGFR3c 
complexes has provided key insights into the 
unique FGFR binding promiscuity of FGF1 (Olsen 
et al., 2004). 
Expression 
Although first isolated from brain and pituitary on 
the basis of their ability to induce fibroblasts 
proliferation, FGF1 is widely expressed in 
developing and adult tissues (Gospodarowicz, 
1974; Gospodarowicz, 1975; Gospodarowicz et al., 
1978; Itoh and Ornitz, 2004). 
Immunohistochemical staining has shown that 
colorectal and gastric tissues, both normal and 
tumor, express FGF1, and the immunoreactivity is 
mainly cytoplasmic (el-Hariry et al., 1997). Various 
amounts of FGF1 are detected in hepatocellular 
carcinoma, whereas it cannot be detected in normal 
(Chow et al., 1998). FGF1 mRNA is detected in 
several types of breast epithelial cell lines such as 
normal (NMEC), transformed (HBL-100) (Renaud 
et al., 1996) and cancer cell lines MCF7, BT-20, 
MDA-MB-231 (Penault-Llorca et al., 1995; Renaud 
et al., 1996), while BT474, T47D and ZR75.1 do 
not express FGF1 mRNAs (Penault-Llorca et al., 
1995). 
 
Figure 3. Domaine structure of FGF1. FGF1 contains a nuclear localization signal (NLS) at N-terminal region and heparin 
binding site is located C-terminal. 
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Figure 4. Crystal structure of FGF1. Ternary structures are depicted by its crystal structure and representative residues for the 
binding to its receptor (blue) and heparin (red) are shown. 
 
Localisation 
FGF1 lacks the classical signal sequence, since it 
employs non-classical pathway to be secreted. 
FGF1-S100A13-SYT complex formation is 
required for passing through the cell membrane 
(Mouta Carreira et al., 1998; Tarantini et al., 1998; 
Landriscina et al., 2001). Secreted extracellular 
FGF1 can be internalized following its binding to 
cell surface receptors by the clathrin-mediated 
pathway (Wiedlocha and Sørensen, 2004). FGF1 
induces FGF receptor translocation from the cell 
membrane to the nucleus upon interaction with its 
receptor during the G1 phase of the fibroblast cell 
cycle (Prudovsky et al., 1994). FGF1 could be 
enters the nucleus by its putative nuclear 
localization sequence (NLS) (Imamura et al., 1990; 
Rodriguez-Enfedaque et al., 2009). Other groups 
suggest that nuclear translocation of FGF1 is 
controled not only by NLS, but also an additional 
sequence which prevents endogenously expressed 
FGF1 from NLS dependent translocation to the 
nucleus, and also FGF1 could move to the nucleus 
by free diffusion because a molecular weight of 
FGF1 is only 16500 (Zhan et al., 1992; Cao et al., 
1993). 
Function 
FGF1 is a mitogen for numerous different cell types 
in vitro. FGF1 has been implicated in a range of 
physiological processes, including development, 
morphogenesis, wound healing and angiogenesis 
(Beenken and Mohammadi, 2009). However, 
FGF1/FGF2 double-knockout mice do not exhibit 
any of the phenotypic abnormalities. This results 
suggest that the developmental and physiological 
roles of FGF1 are highly restricted, even though its 
functions remain unclear (Miller et al., 2000). 
FGF1 binds to integrin ανβ3 (Mori et al., 2008), 
and the integrin-binding site of FGF1 overlapps 
with the heparin-binding site (but not identical). 
The FGF1 mutant that does not bind to ανβ3 
(R50E) is dominant-negative (antagonistic), while it 
still binds to FGFR1 and heparin (Yamaji et al., 
2010). FGF1 induces integin-FGF1-FGFR ternary 
complex, but R50E does not (Yamaji et al., 2010). 
R50E suppresses angiogenesis and tumorigenesis 
(Mori et al., 2013). 
Homology 
Length of FGFs is in the range of 150 to 300 amino 
acids. The conserved core 120-amino acid have 
been shown a 30-60% identity (Itoh and Ornitz, 
2004; Itoh and Ornitz, 2007). 
Implicated in 
Gastrointestinal tumor 
Note 
FGF1 is overexpressed in 42% of colorectal 
adenomas, 76% of colorectal cancers, and 54% of 
gastric cancers as compared to the normal mucosal 
tissues. These results imply that overexpression of 
FGF1 often arises in a human colorectal and gastric 
cancers. FGF1 may play a role in the progression of 
these tumours (el-Hariry et al., 1997). Cancer-
associated fibroblasts expressing fibroblast 
activation protein (FAP) is implicated in the 
invasive behavior of colorectal cancer. FAP 
enhances fibroblast cells to produce FGF1 and 
activates FGFR3 of colon cancer cells in vitro 
resulted in the increased cell migration and invasion 
(Henriksson et al., 2011). 
Breast cancer 
Note 
The majority of breast cancer, including cancer 
adjacent cells expresses active FGF1 protein (Smith 
et al., 1994); however, mRNA of FGF1 is 
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expressed higher level in benign neoplastic and 
hyperplastic tissue than in malignant tissue 
(Anandappa et al., 1994). Another group 
demonstrates that the extent and intensity of 
immunoreactivity of FGF1 in cancer cells is much 
greater than those of cells from fibroadenoma or 
mastopathy (Yoshimura et al., 1998). FGF1 is 
detected in epithelial cells of breast fibroadenomas, 
and FGFR4 is expressed both in epithelial cells and 
stromal fibroblasts. These suggest a 
paracrine/autocrine regulation of epithelial and 
stromal cells of fibroadenomas through an FGF1-
FGFR4 interaction (La Rosa et al., 2001). 
Nerve injury 
Note 
FGF1 is one of neuronotrophic factor and enhances 
nerve regeneration process (Walter et al., 1993). 
FGF1 increases the branching number of 
myelinated axons that regenerate damaged neurons 
and FGF1 also induces the axon elongation of 
primary sensory and motor neurons through the 
nerve guide in animals (Cordeiro et al., 1989). 
Protein expression profiles throughout 28 days of 
peripheral nerve regeneration reveals that FGF1 
increases throughout the experimental period in the 
both proximal and distal nerve segments (Bryan et 
al., 2012). 
Cardiac ischemia 
Note 
Level of FGF1 in pericardial fluid is associated 
with severe myocardial ischemia. FGF1 is released 
from the myocardial tissue into pericardial result 
from the myocardial ischemia (Iwakura et al., 
2000). FGF1 may contribute to the functional 
preservation for the myocardium damage. In fact, 
treatment with FGF1 by extravascular delivery 
system increases coronary flow in the artificially 
constricted territory (Lopez et al., 1998), and also 
systemic bolus of FGF1 immediately after 
myocardial ischemia reduces apoptosis in animal 
model (Cuevas et al., 1997). 
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